INTRODUCTION
============

Previous studies in our laboratory have investigated the role of IgE and the immune response to specific viruses including: Parvovirus B19 in children [@B1], HIV-1 in HIV-1 seropositive, non progressor pediatric patients [@B2], [@B3], Varicella Zoster Virus (VZV) [@B4], [@B5], as well as in both children and adults with a past history of chicken pox infection or VZV vaccination [@B6]. Other studies in our laboratory also identified IgE anti- spirochete antibodies (*B. Burgdorferi*) and its persistence one year later in serum of lyme-infected children [@B7].

Studies in humans and animals reported by others have identified IgE anti-virus antibodies in several viral infections including respiratory syncytial virus (RSV) [@B8], [@B9], parainfluenza [@B10], HTLV-1 [@B11], Puumala virus [@B12], HSV-1, HSV-2, and Epstein-Barr virus [@B13], and blue tongue virus in cattle [@B14].

Studies of Grunewald, *et al*., reported Influenza A virus-specific IgE antibodies in the serum of infected mice, and showed local anaphylaxis after rechallenge with the Influenza A virus antigen; these mice developed virus-specific mast cell degranulation in the skin [@B15]. Recent studies of Davidsson, *et al* demonstrated in healthy human subjects, with no known allergy, IgE responses against Influenza A [@B16]. No anaphylactic reactions were associated with vaccination [@B16]. However, serum IgE levels were increased after Influenza vaccination, which might indicate a participation of IgE in viral defense [@B16]. Earlier studies of Dobber, *et al* also found that IgE specific Influenza virus antibodies were increased after influenza vaccination in mice [@B17]. Interestingly, low levels of total Influenza virus-specific antibody secreting cells (ASCs) have been reported in blood, tonsils, and nasal mucosa of non-allergic study subjects that had not been recently vaccinated or naturally infected with Influenza virus [@B18]. In their earlier studies, they found that Influenza virus-specific antibodies in the oral fluid (saliva) consist mainly of secretory IgA (sIgA) [@B19].

This study is the first, to our knowledge, to describe the long term persistence of IgE anti-Influenza virus antibodies in serum of IgE positive and negative vaccinated pediatric and adult subjects, approaching two years post vaccination. The exact role of IgE in Influenza virus infection remains to be elucidated; however, the presence of IgE anti Influenza virus antibodies several months post vaccination warrants further investigation of the biological significance, if any, of these antibodies.

MATERIALS AND METHODS
=====================

Patient specimen description
----------------------------

Peripheral blood (3 ml total) was obtained from both pediatric (N=3) (m/f, 14-16 yrs old) and adult (N=3) (m/f, 41-49 yrs old) Caucasian subjects from the SUNY Downstate Allergy Clinic, who were both atopic and non atopic, with normal (\<100 IU/mL) or elevated serum IgE levels. Atopic subjects were skin prick positive (N=2) for environmental (e.g. mixed tree and grass, ragweed, weeds, and dust mite) or food allergens. Exclusion criteria included food allergy to egg and antibiotics. At the time of study, the subjects had not received allergy therapy, and were not being treated with any medication. Subjects did not have a past history of parasite infection. Approval was obtained from the SUNY Downstate Institutional Review Board, and the procedures followed were in accordance with institutional guidelines involving human subjects.

Vaccine description
-------------------

All adults were vaccinated with Influenza Virus Vaccine Fluzone^®^(inactivated Influenza Virus Vaccine, 2009-2010 Formula; Sanofi Pasteur Inc., Swiftwater, PA) and children were vaccinated with Flumist^®^ (live attenuated Influenza Virus Vaccine, Intranasal, 2009-2010 Formula; MedImmune,LLC, Gaithersburg, MD). Each 0.25 mL dose of Fluzone vaccine contains 7.5 mcg of influenza virus hemagglutinin (HA) and each 0.5 mL dose contains 15 mcg HA from each of the following 3 viruses: A/Brisbane/59/2007, IVR-148 (H1N1), A/Uruguay/716/2007/, NYMC X-175C (H3N2) (an A/Brisbane/10/2007-like virus), and B/Brisbane/60/2008. Each 0.2 mL dose of Flumist intranasal spray contains 10 FFU (fluorescent focus units) of live attenuated influenza virus reassortants of each of the three strains for the 2009-2010 season: A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008.

Time post vaccination for subjects was 2-20 months. Past history of vaccination was confirmed by positive immunoblot for IgG anti Influenza virus. (See methods below.)

Total serum IgE
---------------

Blood was collected and immunoglobulin (Ig) levels (IgE) were detected in serum (Quest Diagnostics, Inc. Teterboro, NJ), which was performed according to manufacturer\'s recommendation. Reference range for healthy adult or child serum: IgE: 20-100 IU/mL.

Influenza virus serum antibody detection: Immunoblot
----------------------------------------------------

The presence of IgE or IgG anti-Influenza antibodies was determined by immunoblot (dot blot), as previously described [@B5], [@B6]. Briefly, Influenza virus vaccine Fluzone (5ul) (90 ug/mL protein conc.) was pipetted onto nitrocellulose membrane strips (BIO-RAD Laboratories, Hercules, CA) and let dry. Nitrocellulose membrane was then soaked in a 5% milk powder (Immunetics Inc., Boston, MA) solution (Tween 20 (0.05% Tween20 (Sigma) in tris buffered saline (20mM Tris-HCL (Sigma), 150 mM NaCl, pH7.5 (Sigma).

Detection of IgE anti Influenza
-------------------------------

Nitrocellulose membranes were then incubated with serum samples (100 ul) (diluted in 2 ml TBS-Tween 20) for 1 hr at room temperature, after which goat IgG fraction to human IgE (MP Biomedicals, Solon, OH), diluted 1:20-40 in TBS-Tween 20 and 1% milk in TBS-Tween 20 (1 ml), was added to membranes, and incubated overnight on a shaker at room temperature.

Detection of anti Influenza IgG
-------------------------------

IgG Fraction goat anti human IgG (heavy and light chains specific) (ICN/Cappell, West Chester, PA), diluted 1:100 in TBS-Tween 20 and 1% milk in TBS-Tween 20 (1ml) was added to membranes and incubated for one hour on a shaker at room temperature. The membranes were then washed three times with TBS-Tween 20.

For detection and development of both IgG and IgE isotypes: nitrocellulose membranes were then incubated with rabbit anti-goat peroxidase labeled antibody (whole molecule) (Cappel, West Chester, PA), diluted 1:2000 in TBS-Tween 20 and 1% Milk for 1 hour on a shaker, washed 3 times with TBS-Tween 20, and then developed in TMB substrate solution (2 ml). The membranes were then removed from the TMB substrate solution, at which time they were read dried, and scanned (Gel Doc 2000 System with specific The Discovery Series: Quantity One software BioRad, Hercules, CA).

Cytokine determination
----------------------

Serum cytokines \[Interleukin-2 (IL-2), Interferon gamma (IFN-γ), Interleukin-4 (IL-4), Interluekin-10 (IL-10)\] were determined by sandwich ELISA (Biosource, Camarillo, CA) according to the manufacturer\'s protocol.

Statistical Analysis
--------------------

Cytokine determinations from vaccinated and non vaccinated subjects were compared on each variable. Significance between variables was determined using student\'s t-tests. A p value of \<0.05 was considered statistically significant for all comparisons. The degree of association between these measures was assessed using Pearson\'s correlations. Statistical analyses were performed using SPSS for Windows, version 10.0 software (SPSS Inc., Chicago, IL).

RESULTS
=======

1. Characteristics of Study Subjects {#Section1}
------------------------------------

Serum IgE levels and IgE and IgG anti-Influenza virus antibodies were studied in children (N=3) (m/f 14-16 y/o) and adults (N=3) (m/f, 41-49 y/o) approaching two years post vaccination, as well as in non infected, non-vaccinated children (N=2) (m/1 y/o) (Table [1](#T1){ref-type="table"}).

2. Total IgE {#Section2}
------------

Total serum IgE levels were both normal and elevated in adults and children vaccinated with Influenza virus. Children with no history of either Influenza virus infection or vaccination had serum IgE levels which were low (Table [1](#T1){ref-type="table"}).

3. Anti-Influenza Abs {#Section3}
---------------------

**IgG**. Serum obtained from subjects who were vaccinated had positive dot blots for IgG anti-Influenza virus antibodies (Data not shown). In contrast, serum from non-infected, non-vaccinated (control) subjects did not contain IgG anti-VZV antibodies.

**IgE.** Serum obtained from 5 out of 6 vaccinated subjects (83%) had positive dot blots for IgE anti-Influenza virus antibodies; they had either elevated or normal levels of serum IgE (Table [1](#T1){ref-type="table"}) (Fig [1](#F1){ref-type="fig"}, lanes 1, 2). In contrast, serum from non-infected, non vaccinated subjects did not contain IgE anti-Influenza virus antibodies (Fig [1](#F1){ref-type="fig"}, lane 3); they had low levels of serum IgE.

4. Cytokines in serum {#Section4}
---------------------

Similar levels of IL-2, IFN-γ, IL-4, and IL-10 cytokines were detected in serum of vaccinated compared with non vaccinated subjects (p\>0.05), as well as between vaccinated adults compared with vaccinated children, compared with non vaccinated subjects (p\>0.05) (data not shown).

DISCUSSION
==========

The present studies are the first to describe the long-term persistence of IgE anti-Influenza virus antibodies in vaccinated children and adults, with normal and elevated levels of serum IgE, approaching two years post vaccination.

Influenza viruses are respiratory pathogens which belong to the Orthomyxoviridae family [@B20], and are a group of negative-stranded, segmented RNA viruses [@B20]. Three types of influenza virus (A, B, C) have been reported which are categorized by their antigenic differences in the nucleoprotein and matrix protein [@B21]. Influenza A and B viruses commonly cause disease in humans [@B21]. The Influenza A virus has surface antigens, but diverse subtype-specific, haemagglutinin (HA) and neuraminidase (NA); antibodies to these viral antigens mediate immunity to infection [@B21]. When an influenza virus infection is first experienced, an IgM response is elicited to both type and subtype-specific antigens of influenza virus [@B22]; subsequent infections or vaccinations later in life to the type-specific antigens would be restricted to IgG responses [@B22].

Influenza virus causes annual epidemics, which generally occur in the winter months in the Northern hemisphere [@B21], and is spread from person to person by either direct contact with a virus infected individual, or by virus droplets from sneezing or coughing [@B21]. An uncomplicated case of influenza will resolve within 1-2 weeks; however, in patients with other underlying medical conditions, infection with influenza may result in hospitalization and death [@B21].It has been reported that influenza has been responsible for high numbers of morbidity and mortality in the United States [@B23]. All age groups can be infected with Influenza virus, but children have the highest infection rates [@B24]. In the United States, vaccination is recommended for people with increased rate of medical conditions (50-64 y/o), and for children 6 months and older [@B21], [@B25]. In some countries, vaccination is recommended for health care workers, and caregivers in nursing homes and assisted living facilities [@B21].

It is well known that both humoral (mucosal and serum antibody responses), as well as cellular immune responses play a role in resistance to influenza infection [@B26]-[@B29]. sIgA, as well as IgM are the neutralizing antibodies in the mucosa that prevent virus entry and inhibit virus replication [@B30]. During primary infection, IgG, IgA and IgM- specific to HA have been detected in nasal washings by enzyme-linked immunosorbent assay, although IgA and IgM were more frequently detected than IgG [@B30]; IgE-specific to HA was not studied. Natural wild type Influenza virus infection can stimulate a local IgA response, which can last 3-5 months, as well as influenza-specific IgA-committed memory cells [@B30]. Levels of neutralizing antibodies induced by live virus vaccine correlate with resistance to infection after challenge with wild-type virus [@B28]. Previous studies by others reported that during primary infection, IgG, IgA, and IgM can be detected within 10-14 days [@B30]. Two weeks post infection, levels of IgA and IgM peak, and then begin to decline, whereas four to six weeks post infection, levels of IgG peak [@B30]. In the primary response IgG and IgM are dominant, and after secondary infection, IgG and IgA are the predominant immunoglobulin isotypes detected in serum [@B21], [@B30].

It has been reported that in vaccinated individuals, 2-6 days post vaccination, serum antibody responses to trivalent (inactivated) influenza vaccine were detected, peaked 2-3 weeks post vaccination, and then was two-fold lower 6 moths post vaccination [@B31]; influenza specific IgG1 antibodies were the dominant antibody detected, as well as lower levels of IgM and IgA [@B31]; IgE antibodies were not studied. It should be mentioned that in the United States, mucosal vaccines for Influenza are now available for children, and target the mucosa and lymphoid tissue, which are areas where early infection occurs [@B32]. In other investigations, it has been shown that influenza virus-specific antibodies in saliva consist of SIgA1, which is first detected 5-7 days after vaccination, and the elevated antibody response lasts for 3-5 days [@B19], [@B31]. However, an increase of H1N1 and B strains influenza virus antibodies has been found in oral fluid 7 days post vaccination [@B18]. Levels of influenza virus-specific ASCs in blood is low before vaccination, compared with levels in tonsils and nasal mucosa [@B18]; after vaccination, this level increased nearly 4 log~10~[@B18]. Live, attenuated influenza vaccines induce both mucosal and systemic responses [@B21]. The cold-adapted (CA) live, attenuated vaccines are administered intranasally in children and provide protective immunity [@B21]. After CA vaccination, serum antibody responses and/or virus shedding has been noted in most recipients [@B21].

In the present study, vaccinated adult (live attenuated vaccine) and pediatric (nasal vaccine) patients (2-20 months post vaccination), with both normal and elevated serum IgE levels, had specific IgG and IgE anti-influenza antibodies, detected by immunoblot. Of notable interest under study, is the long-term persistence of these antibodies (approaching two years post vaccination). Although prior literature suggests that Influenza virus specific IgG antibodies wane 6 months post vaccination [@B31], we were able to detect both IgG and IgE specific Influenza virus antibodies up to two years post vaccination. It is conceivable that the detection of IgG and IgE reported here (dot blot technology) affords a greater level of sensitivity than previous reports which employ ELISA based approaches. In this manner our data are consistent with the detection of other reports with respect to immunoglobulin anti-influenza presence. However, in our studies, the levels of Ig anti-influenza antibodies over time were not determined.

Given the findings of this study, the presence and persistence of IgG and IgE anti-influenza antibodies in the serum from those with normal and elevated levels of IgE are understandable. Our findings appear to be of importance and relevant because previously described studies from our laboratory [@B33] have shown the presence of IgE anti-cancer antibodies present in patients with both normal and elevated IgE levels which were able to mediate antibody dependent cell mediated cytotoxicity against cancer cells *in vitro*. These responses were not correlated with total serum IgE levels. We therefore speculate that it is not the total IgE levels that are important but rather the fraction of IgE anti-influenza antibodies as a percentage of the total IgE pool that are responsible for mediating any effects. Our discovery also suggests that the IgE molecule has evolved to serve various beneficial functions, including anti-viral. However, at present, it is unclear how IgE promotes its activity in these viruses.

Although IgE anti-viral responses are demonstrated, the limitations of this study include small sample size, and the lack of racial disparity. All the subjects were Caucasian and in good health. It could be that the immunoglobulin anti-viral responses may differ in vaccinated subjects of African American or Hispanic descent as has been shown in other vaccine trials (34). Additional studies towards understanding immunoglobulin anti-viral responses in subjects and patients with co-morbidities or immunocompromise are warranted.

The results presented here suggest that IgE is associated with anti-influenza immunity and their memory responses. Further studies are necessary to elucidate the role of immunoglobulins in influenza infection and to determine possible functional roles of IgE in this disease and its relationship to viral pathophysiology.

![**Immunoblot analysis of IgE anti-influenza virus antibodies.**Serum from subjects with past history of influenza virus vaccination or no infection was incubated with nitrocellulose strips containing influenza virus vaccine antigen (see Materials and Methods). Lane 1: representative blot of subject vaccinated with influenza virus vaccine, who had elevated serum IgE levels (\>100 IU/ml). Lane 2: representative blot of subject vaccinated with influenza virus vaccine who had low serum IgE levels (\<100 IU/ml). Lane 3: control subject, no history of infection or vaccination.](ijmsv08p0239g01){#F1}

###### 

CHARACTERISTICS OF STUDY SUBJECTS AND SERUM IgE LEVELS

  Patient   Sex/Age (years)   Form of Influenza virus inoculation (Fall 2009)   Serum IgE levels (IU/ml)   IgE anti- Influenza virus (+/-)^\#^   IgG anti-Influenza virus (+/-)^\#^
  --------- ----------------- ------------------------------------------------- -------------------------- ------------------------------------- ------------------------------------
  1         F (18)            Flumist^®1^                                       154\*                      \+                                    \+
  2         F (41)            Fluzone^®2^                                       15                         \+                                    \+
  3         M (44)            Fluzone                                           232\*                      \+                                    \+
  4         M (14)            Flumist                                           34                         \+                                    \+
  5         M (16)            Flumist\*\*                                       132                        \-                                    \+
  6         F(49)             Fluzone                                           34                         \+                                    \+
  7         M (1)             None                                              14                         \-                                    \-
  8         M(1)              None                                              15                         \-                                    \-

Patients were inoculataed with either ^1^Flumist^®^ (live attenuated Influenza Virus Vaccine),

^2^ Fluzone^®^(inactivated Influenza Virus Vaccine) or none. \*Patient skin test (skin prick) positive for food or environmental allergens. Reference range for healthy adult or child serum: IgE: 20-100 IU/mL.\*\*Was given Flumist in 2008.

\# Immunoblot (See Material and Methods).
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